Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on January 17, 2008. The report addresses corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial data.
Material Changes
- Resignation: George Drazenovic resigned as a Director and Secretary of the company effective January 17, 2008.
- Appointment: Leonard Sank, an existing Director, was appointed as the new Secretary of the company to replace Mr. Drazenovic.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the officer and director changes described above.
Investor Verification Checklist
- Confirm the effective date of George Drazenovic's resignation and Leonard Sank's appointment.
- Review the company's Board of Directors composition to ensure the vacancy left by Mr. Drazenovic is addressed.
- Check for any subsequent filings regarding the compensation arrangements for the new Secretary, as this item is often disclosed in conjunction with such appointments.